Scaling Up Insulin Pen Production With DROFEN MACHINERY: A Guide For CDMOs Moving From Pilot To Commercial Manufacturing

Article summary:

DROFEN MACHINERY is a specialized turnkey project-delivery partner focused on two core production lines: injection pen assembly lines and PP plastic syringe filling lines. We bridge the gap between mechanical assembly and pharmaceutical compliance. Through our experience in deploying commercial-scale lines, we know that moving from a pilot scale (producing a few thousand units for clinical trials) to commercial manufacturing (producing tens of millions of units annually) is not simply a matter of running machines faster. It requires a fundamental shift in engineering strategy and project execution.

 

A common mistake made by CDMOs during scale-up is attempting to linearly expand their pilot processes. Pilot lines often rely heavily on manual or semi-automated interventions, which are acceptable for small batches but introduce unacceptable variability at high speeds.

When scaling up, the mechanical forces applied to the device components-such as the torque required to attach the pen cap or the force needed to insert the cartridge-must be tightly controlled. At speeds of 160 units per minute or higher, even minor deviations can lead to cracked glass cartridges, deformed plastic components, and a high reject rate.

 

To ensure a successful transition to commercial manufacturing, CDMOs must prioritize the following factors when selecting their assembly line architecture:

 

Commercial assembly lines must be adaptable. A modular design allows CDMOs to add or modify stations (such as labeling, secondary packaging, or specific inspection cameras) without re-engineering the entire line. This flexibility is crucial for CDMOs handling multiple client projects with varying device formats.

 

At commercial speeds, 100% in-process control is non-negotiable. Every critical assembly step must be monitored in real-time using servo-driven force-displacement sensors and high-speed vision systems. This ensures that defective units are identified and rejected immediately, rather than discovering them during final quality assurance checks.

 

Commercial manufacturing requires robust data management to comply with FDA 21 CFR Part 11 and EU GMP Annex 11. The assembly line must seamlessly integrate with the facility's Manufacturing Execution System (MES) or Supervisory Control and Data Acquisition (SCADA) system to provide complete batch traceability and electronic audit trails.

 

Scaling up is a high-stakes endeavor. If a CDMO purchases pre-assembly equipment from one vendor and final assembly equipment from another, they bear the burden of integrating these disparate systems. This "integration gap" often leads to delayed timelines and unexpected costs.

 

This is where the value of a turnkey project-delivery partner becomes apparent. DROFEN MACHINERY is a specialized turnkey project-delivery partner focused on two core production lines: injection pen assembly lines and PP plastic syringe filling lines. We bridge the gap between mechanical assembly and pharmaceutical compliance.

 

By providing both the pre-assembly equipment (capable of a stable 160 pens/min) and the final assembly lines (operating at 160 units/min), along with comprehensive platform coordination and regulatory validation support (IQ/OQ/PQ templates), we eliminate the integration risks associated with scale-up. Our approach allows CDMOs to focus on their core competency-pharmaceutical manufacturing-while we handle the complexities of the equipment engineering and project delivery.

 

Scaling up insulin pen production is a complex engineering challenge that demands more than just fast machinery. It requires a holistic approach that integrates modular design, advanced IPC, and robust data management. By partnering with a specialized project-delivery partner rather than a traditional equipment supplier, CDMOs can navigate the scale-up process with confidence, ensuring rapid time-to-market and uncompromised product quality.